Internal Medicine, Endocrinology, Diabetes, & Metabolism · Huntington Beach, CA
NPI
1699862102
Since 2006
Specialty
Internal Medicine, Endocrinology, Diabetes, & Metabolism
Code 207RE0101X
Group practices
2
Medicare group memberships
Hospitals
4
Hospital affiliations
18821 Delaware St, Suite 202
Huntington Beach, CA, 92648
Phone (714) 375-5572
Groups this clinician bills Medicare through
Medicare paid, 2024
$98K
890 services
Medicare patients, 2024
433
Average age 76
Drug cost, 2024
$4.7M
13,684 prescriptions
Company payments, 2025
$8,986
From 25 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Paul D Rosenblit was code 99214 (office e&m - established), 772 times for 404 patients. In total Paul D Rosenblit billed 890 services in 13 codes, and Medicare paid $98K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2019-08-20.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 99214 Office E&M - Established | Office | 772 | 404 | $106.42 | $82K |
| 99205 Office E&M - New | Office | 40 | 40 | $186.74 | $7,470 |
| 99215 Office E&M - Established | Office | 16 | 15 | $163.32 | $2,613 |
| 99223 Hospital E&M - Initial | Facility | 14 | 13 | $153.94 | $2,155 |
| 99213 Office E&M - Established | Office | 13 | 13 | $73.92 | $961 |
By year: 2022 $109K for 1,060 services; 2023 $105K for 1,010 services; 2024 $98K for 890 services.
Medicare prescription drug claims, 2024
In 2024, the drug Paul D Rosenblit prescribed most often to Medicare patients was Ezetimibe, with 1,309 prescriptions and refills. In total Paul D Rosenblit wrote 13,684 Medicare prescriptions that cost $4.7M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Ezetimibe Generic | 1,309 | 3,692 | 391 | $40K |
| Pioglitazone Hcl Generic | 1,182 | 3,346 | 349 | $16K |
| Levothyroxine Sodium Generic | 1,070 | 3,073 | 294 | $15K |
| Rosuvastatin Calcium Generic | 928 | 2,662 | 291 | $19K |
| Atorvastatin Calcium Generic | 902 | 2,519 | 267 | $10K |
| Metformin Hcl Generic | 765 | 2,167 | 243 | $7,953 |
| Jardiance Empagliflozin | 661 | 1,603 | 186 | $910K |
| Ozempic Semaglutide | 436 | 737 | 96 | $682K |
| Trulicity Dulaglutide | 371 | 678 | 89 | $647K |
| Metoprolol Succinate Generic | 309 | 862 | 91 | $4,317 |
| Losartan Potassium Generic | 282 | 785 | 86 | $2,710 |
| Amlodipine Besylate Generic | 278 | 771 | 92 | $1,256 |
| Farxiga Dapagliflozin Propanediol | 252 | 564 | 65 | $305K |
| Lisinopril Generic | 240 | 662 | 70 | $1,579 |
| Metformin Hcl Er Metformin Hcl | 222 | 624 | 74 | $3,342 |
Brand drugs: 3,928 claims; generic drugs: 9,542 claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Paul D Rosenblit $8,986 ($8,986 in general payments such as food, travel and fees) from 25 companies. The largest payer was Ionis Pharmaceuticals, Inc. with $6,926.
| Company | Payments | Amount |
|---|---|---|
| Ionis Pharmaceuticals, Inc. IONS | 4 | $6,926 |
| Novo Nordisk Inc NVO | 9 | $286 |
| Amgen Inc. AMGN | 8 | $278 |
| Bayer Healthcare Pharmaceuticals Inc. BAYN.DE | 9 | $259 |
| Ascendis Pharma Endocrinology Inc ASND | 5 | $201 |
| Corcept Therapeutics CORT | 3 | $159 |
| Recordati_rare_diseases_inc. | 1 | $132 |
| Kyowa Kirin, Inc. 4151.T | 1 | $122 |
| Regeneron Pharmaceuticals, Inc. REGN | 1 | $75.3 |
| AstraZeneca Pharmaceuticals LP AZN | 1 | $66.09 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.